Market Research Report
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
|Published by||FirstWord||Product code||326365|
Delivery time: 1-2 business days
|Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders|
|Published: February 1, 2015||Content info:||
Based on survey results from 150 rheumatologists, dermatologists, and gastroenterologists in UK, France, Germany, Spain and Italy, ‘Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders’ offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal antibodies (mAbs) can best meet physician needs on various supporting roles. In addition, gain comparative insights on the Medical Affairs teams' roles from the originator anti-TNF companies.
Using Need-Gap analysis, a proprietary analytics tool to FirstWord, areas of unmet need are identified, which provide valuable guidance on opportunities for corporate and brand positioning and communication.
With the launch of biosimilar Remicade, and anti-TNF mAb, currently taking place across the major markets of Europe - France, Germany, Italy, Spain, the UK; EU5 - biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs' strategy for their products. Refining performance through smarter delivery, higher quality interaction, and effective communication with rheumatologists, dermatologists and gastroenterologists becomes vital for ensuring optimal performance levels of Medical Affairs teams.
Filled with charts and up-to-the-minute survey analysis, this report offers: